Cardioneuroablation for the treatment of symptomatic bradycardia mediated by the cardiac autonomic nervous

[1] Tresch DD, Fleg JL. Unexplained sinus bradycardia: clinical significance and long-term prognosis in apparently healthy persons older than 40 years. Am J Cardiol 1986; 58: 1009−1013. doi: 10.1016/S0002-9149(86)80029-7 [2]

Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. Circulation 2019; 140: e382−e482.

[3] Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021; 42: 3427−3520. doi: 10.1093/eurheartj/ehab364 [4] Qin M, Zhang Y, Liu X, et al. Atrial ganglionated plexus modification: a novel approach to treat symptomatic sinus bradycardia. JACC Clin Electrophysiol 2017; 3: 950−959. doi: 10.1016/j.jacep.2017.01.022 [5] Pachon JC, Pachon EI, Pachon JC, et al. "Cardioneuroablation"-new treatment for neurocardiogenic syncope, functional AV block and sinus dysfunction using catheter RF-ablation. Europace 2005; 7: 1−13. doi: 10.1016/eupace/7.Supplement_1.1-a [6] Zipes DP. Ablation of atrial gangionated plexi to treat symptomatic sinus bradycardia. JACC Clin Electrophysiol 2017; 3: 960−961. doi: 10.1016/j.jacep.2017.02.010 [7] Rivarola EW, Scanavacca M. Atrial ganglionated plexus modification: a novel approach to treat symptomatic sinus bradycardia. JACC Clin Electrophysiol 2018; 4: 287−288. doi: 10.1016/j.jacep.2017.10.015

Comments (0)

No login
gif